# S2k guideline: Rosacea

Professional Societies involved: DDG – Deutsche Dermatologische Gesellschaft (German Dermatological Society)

BVDD – Berufsverband der Deutschen Dermatologen (Professional Association of German Dermatologists) SGDV – Schweizerische Gesellschaft für Dermatologie und Venerologie (Swiss Society for Dermatology and Venereology)

GD – Gesellschaft für Dermopharmazie (Society for Dermatopharmaceutics)

Deutsche Rosazea Hilfe e.V. (German Rosacea Aid)

AWMF-Registry Number: 013-065 Validity: This guideline is valid until 31.12.2026. Benjamin M. Clanner-Engelshofen<sup>1</sup>, Dominik Bernhard<sup>1</sup>, Sonja Dargatz<sup>2</sup>, Michael J. Flaig<sup>1</sup>, Uwe Gieler<sup>3</sup>, Maria Kinberger<sup>4</sup>, Winfried Klövekorn<sup>5</sup>, Anne-Charlotte Kuna<sup>1</sup>, Severin Läuchli<sup>6</sup>, Percy Lehmann<sup>7</sup>, Alexander Nast<sup>4</sup>, Uwe Pleyer<sup>8</sup>, Martin Schaller<sup>9</sup>, Helmut Schöfer<sup>10</sup>, Martin Steinhoff<sup>11</sup>, Thomas Schwennesen<sup>2</sup>, Ricardo Niklas Werner<sup>4</sup>, Manfred Zierhut<sup>12</sup>, Markus Reinholz<sup>1</sup>

(1) Department and Clinic for Dermatology and Allergology, University Hospital Munich, LMU Munich, Germany

(2) Deutsche Rosazea Hilfe e.V. (German Rosacea Aid), Hamburg, Germany
(3) Vitos Hospital for Psychosomatic Medicine, University Hospital Gießen - Dermatology, UKGM Gießen, Gießen, Germany

(4) Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
 (5) Dermatological practice, Gilching, Germany

(6) Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
(7) Center for Dermatology, Allergology and Dermatosurgery, HELIOS University
Hospital Wuppertal, Witten/Herdecke University, Wuppertal, Germany
(8) Department of Ophthalmology, Charité – Universitätsmedizin Berlin, corporate
member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
(9) Department of Dermatology, University Hospital Tübingen, Eberhard Karls
Universität Tübingen, Tübingen, Germany

(10) German Clinic for Diagnostics (DKD, Deutsche Klinik für Diagnostik) Dermatology, Helios Kliniken Wiesbaden, Wiesbaden, Germany

(11) Weill Cornell Medicine-Qatar, Cornell University, Ar-Rayyan, Qatar

(12) Department of Ophthalmology, University Hospital Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Germany

#### Summary

This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and flushing. Later, the inflammatory component predominates, with persistent erythema with follicular papules, papulopustules and pustules. The development of phyma, which usually occurs on the acral localizations, is the most severe manifestation. For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e. V., recommends the avoidance of trigger factors and topical applications of metronidazole, azelaic acid or ivermectin. For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be used. Systemic therapy is recommended for therapy-resistant and severe forms of rosacea papulopustulosa. The drug of choice is low-dose doxycycline. Alternatively, low-dose isotretinoin can be recommended. Ocular rosacea should be treated with lid margin hygiene. For topical treatment, ciclosporin eye drops, azithromycin, ivermectin or metronidazole are suggested.

### Introduction

For a standardized representation of the recommendations, the wordings and symbols listed in Table 1 were used.

This guideline is an updated version of the German guideline which was last published in 2013, but has now been upgraded to the level of S2k. Some passages were adopted from the earlier version [2].

### Overview of therapeutic options

The following figure offers an overview of the therapeutic options for rosacea (Figure 1, adapted from [3]).

### Definition

Rosacea is a common, chronic-inflammatory disease which mostly affects the face (especially cheeks and nose, but

occasionally also forehead and chin) but can also involve the eyes. It is most frequently found in middle-aged adults with light skin (Fitzpatrick types I and II). This dermatosis was until recently categorized into distinct subtypes according to clinical presentation, with the subtypes occurring chronologically one after the other. Lately, a classification of rosacea according to defined phenotypes has been recommended

## Epidemiology

There are hardly any reliable data on the epidemiology of rosacea. A British study found an incidence of 165 diagnosed cases per 100,000 inhabitants per year [4].

Prevalence of rosacea differs from study to study. A systematic review with meta-analysis of 41 patient cohorts covering a total number of 26 million persons found prevalences between 0.09 % and 22.41 % with an average of 5.46 % [5]. In Germany, a general prevalence of 2.3 % was

 Table 1
 Strengths of recommendation – wording, symbolism and interpretation (modified in accordance to Kaminski-Hartenthaler et al., 2014 [1]).

Strength of Recom- mendation	Wording	Symbol	Interpretation
<b>Strong</b> recommen- dation <b>in favor</b> of a procedure	"is recommended"	<b>↑</b> ↑	In our opinion, all or nearly all informed people would decide in favor of this procedure. Clinicians need to spend less time with the patient when deciding on this procedure. In most clinical situa- tions, this procedure can be considered a general recommendation.
Weak recommen- dation in favor of a procedure	"is suggested"	1	In our opinion, most informed people would decide in favor of this procedure, but a substantial minority would not. Clinicians and other health professionals need to take more time with the patient to make sure that choosing this procedure with its possible conse- quences reflects the individual patient's values and preferences. Decision procedures in the health care system require in-depth dis- cussion and inclusion of many persons involved in the process.
<b>No</b> recommendation regarding a proce- dure	"may be considered"	0	At this point in time, no recommendation for or against a certain procedure can be given due to certain circumstances – for examp- le lack of evidence, unclear or unfavorable benefit-risk balance, etc.)
Recommendation against a procedure	"is not recommended"	$\downarrow$	In our opinion, all or nearly all informed people would decide against this procedure.




Figure 1 Overview of treatment options (adapted from Schaller et al. 2016) [3].

calculated in 2014, based on statutory health insurance data from a total of 90,800 people. According to this analysis, the highest prevalence found was 6.24 % in the age group between 45 and 60 [6].

Data on the sex distribution of rosacea are conflicting.

Rosacea is most frequently diagnosed in persons with light, Celtic skin (Fitzpatrick I–II) and much less frequently in persons with skin types IV–VI [7, 8]. This however is not due to a lower prevalence but to a larger diagnostic gap since clinical presentation in persons with skin types IV–VI is less clear [7]. A world-wide, systematic review did not find any differences of prevalence according to latitudes [5].

### Pathogenesis

Both genetic and environmental influences contribute to the development of rosacea. The initial mechanisms leading to early forms of rosacea remain unknown. As with other chronic-inflammatory skin diseases, innate and adaptive immune responses as well as the vascular system (blood and lymph system) and the neuronal system play a role. A genetic base for rosacea has been suspected for a long time, indicated by epidemiological data, but has not yet been scientifically proven. Genetic studies on polymorphisms and twin studies indicate that a genetic predisposition for the development of rosacea is very probable [9]. The connection between this predisposition and the trigger factors typical for rosacea (see below) on the molecular level are however still unclear [10–13].

Trigger factors for rosacea and their possible cellular activation pathways are listed in Table 2 [12].

### Clinical presentation

#### General

In the vast majority of cases, rosacea affects the centrofacial skin. The nose and cheeks are affected very frequently, and the forehead and chin frequently. More rarely, adjacent skin areas such as the neck, cleavage, and scalp may also be involved.

Table 2 Trigger factors of rosacea and potential activation pathways.

Trigger factors	Published incidence in (%)	Presumed cellular activation pathways
UV radiation	81	NALP3, TLR2, TRPV4
Emotional stress	79	NALP3, TLR2, TRPV1
"Hot" weather	75	TRPV1,2
Wind	57	NALP3, TLR2, TRPV(?)
Strenuous exercise	56	NALP3, TLR2, TRPV1
Alcohol intake (some but not all patients, depending on alcohol concentration)	52	NALP3, TLR2, TRPV1, TRPV2
Hot baths	51	TRPV1, TRPV2
Very cold weather	46	TRPA1
Spicy food	45	TRPV1
Humidity/osmotic changes	44	TRPV <sub>3</sub> , TRPV <sub>4</sub>
Chages from cold to heat and vice-versa	41	TRPV1
Some cosmetics and skin care products	41	NALP3, TLR2, TRPA1
Hot steam	36	TRPV1
Some types of make-up, some topical medications, some cosmetics (for example those containing formaldehyde)	27	NALP3, TLR2, TRPA1
Medications such as niacin	15	?
Micro-organisms	NR	NALP3, TLR2
Garlic, mustard oil	NR	TRPA1
Psychological stress, excitement	NR	PACAP, SP, CRH, adrenomedullin?
http://www.rosacea.org/patients/materials/triggersgraph.pl	her modified from [12]	

http://www.rosacea.org/patients/materials/triggersgraph.php; modified from [12].

Characteristic symptoms of rosacea include flushing or persistent erythema with teleangiectasia, later also papules, pustules, and lymphedema. Potential other symptoms include plaques, edema, dry skin, phyma of the facial acra, and involvement of the eyes. For the patient, however, the most bothersome symptoms are subjective such as tension, burning, dry skin, stinging, and a sensation of heat [14, 15].

Until recently the disease was categorized into the classic subtypes I to IV, but lately a classification according to symptoms or phenotypes is preferred, facilitating targeted treatment.

#### Classification according to phenotypes

Since 2017, the ROSacea COnsensus Panel has recommended classification according to symptoms, These are categorized into diagnostic symptoms, major symptoms, and minor symptoms [3, 16, 17]. This categorization is modular and flexible and thus much better reflects clinical reality.

Diagnostic symptoms include phymata as well as persistent erythema which deteriorates as a response to triggers – even one of these symptoms allows the diagnosis of rosacea. Major symptoms include flushing, transient erythema which deteriorates as a response to triggers typical for rosacea, papules and pustules, ocular symptoms, and teleangiectasia. Diagnosis of rosacea requires a combination of at least two major symptoms. Minor symptoms are burning, stinging, edema and swelling, as well as a feeling of skin dryness. The symptoms or phenotypes are also assessed according to frequency, duration, intensity, and extent. This assessment is helpful for describing the severity of symptoms [17].

## Special forms

The section on special forms can be found in the AWMF long version.

## Histopathology

The section on histopathology can be found in the AWMF long version.

## General measures

Recommendation	Strength	Consent
It is recommended to avoid indi-	$\uparrow \uparrow$	100 %
vidual provocation factors (trigger		
factors) as far as these can be		
recognized based on disease pro-		
gression.		

Since external factors can substantially aggravate disease progression in rosacea, patients should be informed about avoidable potential trigger factors, and of course these factors should subsequently be avoided.

### UV protection

Recommendation	Strength	Consent
It is recommended to protect af-	$\uparrow \uparrow$	100 %
fected areas (such as skin or eyes)		
from UV exposure, on the one		
hand by avoiding direct sunlight		
and on the other hand by wea-		
ring hats or sunglasses as well as		
sunscreen.		

It is considered proven that rosacea symptoms can be induced by UV exposure which significantly increases the expression of various pro-inflammatory cytokines. Wearing sun hats, avoiding direct sunlight, and using broad-spectrum sunscreen with both UV-A and UV-B protection should be mandatory for daily management of rosacea. This is explained in more detail in the section "dermocosmetics".

#### Food

Recommendation	Strength	Consent
Avoidance of food leading to va-	$\uparrow \uparrow$	100 %
sodilation (such as alcohol, spicy		
food, very hot food or beverages)		
is recommended.		

Factors that may lead to vasodilation or flush symptoms in the face should be avoided. These include alcohol, spicy food, very hot beverages, as well as physical or psychological stress.

## Topical treatment

Recommendation	Strength	Consent
It <b>is recommended</b> to choose the	$\uparrow \uparrow$	100 %
most appropriate active substance,		
concentration, and base for the		
individual patient according to the		
phenotypic characteristics of the		
rosacea, acuity, and skin type.		
For treatment-refractory and severe	$\uparrow \uparrow$	100 %
forms of papulopustular rosacea it is		
recommended to combine topical		
treatment with systemic treatment.		

#### Topical treatment is often sufficient for rosacea with transient or persistent erythema (erythematous rosacea) as well as rosacea with papules, pustules, and occasionally additional erythema (papulopustular rosacea) if the latter is mild to moderate. But even severely inflammatory forms of rosacea are treated with supporting topical medications, in combination with systemic treatment (see section: Combined treatment).

In Germany, the following medications are approved for topical treatment of rosacea: 0.75 % metronidazole in various bases (gel, cream, lotion, micro-emulsion) [18], 15 % azelaic acid gel, 0.33 % brimonidine gel, and 1 % ivermectin cream. All of these have been proven efficacious in randomized, vehicle-controlled double-blind studies or head to head comparisons. Additional topical substances are being used off-label for treating rosacea [3].

Choosing the appropriate substance and its concentration is an individual decision based on rosacea phenotype [17, 19, 20], acuity of the disease, and the patient's skin type.

In severely inflammatory forms, topical treatment is combined with systemic treatment (see section: Combined treatment).

Apart from the medically active substance, the various bases and other ingredients of topical medications will significantly affect tolerability and efficacy of topical medications, since rosacea patients usually have very sensitive and irritable skin. Simultaneous use of cleansing (soaps, syndets) and skincare products (day or night creams, moisturizers, or sunscreens) as well as changes in treatment routines [21] can have a significant impact on the progression of rosacea (see section: Dermocosmetics).

Before topical rosacea treatment is initiated, patients require thorough information on (Table 3):

Table 3Patient information before starting topical rosaceatreatment.

- Method of use (once or twice a day, always after removal of decorative cosmetics)
- Increased sensitivity of facial skin in most rosacea patients (higher rates of hypersensitivity reactions, irritation)
- Duration of treatment (usually many weeks or months)
- Therapeutic goal (absence of symptoms)
- Chronicity of the disease with potential long-term treatment or proactive subsequent treatment
- Known trigger factors such as UV radiation, heat, alcohol, spicy food
- Various phenotypes of the disease [22] and the possible transition into other phenotypes (such as the phyma stage)

#### Brimonidine and oxymetazoline

Recommendation	Strength	Consent
The vasoconstrictor brimonidine (0.33 % gel) <b>is recommended</b> for a purely symptomatic topical tre- atment of rosacea with persistent centrofacial erythema (erythemat- ous rosacea).	<b>↑</b> ↑	100 %
Recommendation	Strength	Consent

#### Brimonidine

Brimonidine tartrate (0.2% eye drops) is a highly selective alpha,-adrenergic receptor agonist. Due to its direct vasoconstrictive activity, it leads to strong, transient constriction of the pathologically dilated dermal arterioles in the facial skin of rosacea patients and thus to disappearance of erythema. This purely symptomatic effect starts about 20-30 minutes after application of a 0.33 % brimonidine gel, reaches a maximum after 3-6 hours, and continues for a total of 8-10 hours with slowly decreasing potency. As the binding of brimonidine to the alpha, receptor diminishes and the substance is metabolized, vasodilation recommences and erythema returns. Efficacy and tolerability of brimonidine were investigated in two parallel randomized, controlled clinical studies with identical design, and confirmed in a long-term study [23-25]. Teleangiectasia, however, cannot be controlled with this substance. Possible negative side effects include local erythema, pruritus, burning skin, and flushing (worsening of symptoms).

Inflammatory processes are also involved in the persistent erythema of erythematous rosacea [26]. Apart from its vasoconstrictive effect, brimonidine also displays anti-inflammatory properties [27].

In early 2014, the European Medicines Agency (EMA) approved brimonidine gel at a concentration of 0.33 % for symptomatic treatment of erythematous rosacea in adult patients. The medication is used once a day in the morning by applying at most one gram of the gel evenly on the face. Undesired topical side effects in the long-term study included worsening of rosacea, indicated by sudden flushing in 9.1 %, worsening of erythema in 6.5 %, and burning of the facial skin in 3.3 % of all patients. As to efficacy in erythema,

brimonidine gel was significantly superior to the gel base alone (p = 0.001) [24].

#### Oxymetazoline

In 2017, the US health authority FDA approved a second vasoconstrictor for the topical treatment of persistent erythema in rosacea, based on controlled, randomized clinical studies [28–31]. Oxymetazoline, a sympathicomimetic, is a selective alpha<sub>1A</sub> adrenoreceptor agonist and has vasoconstrictive and anti-inflammatory properties. Once-daily use of 1 % oxymetazoline hydrochloride cream resulted in a significant decrease (p > 0.001) of erythema by two levels in the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment-for-Rosacea-facial-Redness (SSA) scales. Long-term studies and direct comparisons with standard treatments are not available at this point in time. The medication is not approved in Germany.

None of the substances tested so far, used either topically or systemically, has shown satisfactory results in the treatment of transient rosacea erythema. There is a definite need for prospective, controlled clinical trials in this area.

One study showed that use of brimonidine led to improved quality of life in patients due to reduction of persistent erythema [32].

#### Metronidazole

Recommendation	Strength	Consent
Metronidazole is recommended	$\uparrow \uparrow$	100 %
for topical treatment of rosacea.		

Metronidazole has both antibiotic and antiparasitic efficacy and is the most commonly used topical medication for treating rosacea world-wide. The mechanism of action for this nitroimidazole compound in topical use is not fully understood. Most probably its efficacy is due to the proven anti-inflammatory, immunosuppressive, and antioxidative properties of the substance. Since skin parasites such as demodex mites are involved in the pathogenesis of rosacea, the antiparasitic efficacy of metronidazole may also play a significant role. Its efficacy when used twice a day has been proven in several randomized, placebo-controlled double-blind trials [33, 34] and has been summarized in a Cochrane review [20].

Various topical medications with 0.75 % metronidazole are available in Germany (cream, gel, lotion, emulsion). Their efficacy does not differ significantly [35]. Undesired side effects are comparatively rare after topical application. The most common side effects are local hypersensitivity reactions such as dry skin, erythema, burning, or stinging. Systemic reactions to metronidazole (nausea, impaired sense of taste, peripheral neurological symptoms) are not usually expected from topical use due to low absorption and small treated areas in rosacea, but they have been reported in rare cases.

#### Azelaic acid

Recommendation	Strength	Consent
Azelaic acid is recommended for	$\uparrow \uparrow$	100 %
the topical treatment of rosacea.		

Azelaic acid is a naturally occurring dicarboxylic acid with antibacterial and anti-inflammatory properties and a positive influence on keratinization. In dermatology, it is mainly used for treating acne and rosacea.

In Germany, the 15 % gel preparation but not the corresponding 20 % cream is approved for treating papulopustular rosacea. In the USA, a foam preparation with 15 % azelaic acid is also available [36, 37].

The efficacy of azelaic acid in treating papulopustular rosacea is attributed to its anti-inflammatory properties and normalizing of keratinization [36, 38, 39]. A mildly positive effect on rosacea-induced erythema has also been shown [38, 40]. The gel is applied twice a day.

The most frequently reported undesired side effects include mild to moderate and transient burning, stinging, and pruritus. In a randomized, controlled, double-blind multicenter study, the 20 % azelaic acid cream (which is not approved for rosacea in Germany) has also shown significant superiority of the substance in reducing papules and pustules as compared to the cream base used in the control group [41]. Similar results were found in a double-blind study with the 15 % azelaic acid foam which is also not approved in Germany [37, 38].

#### lvermectin

Recommendation	Strength	Consent
lvermectin is recommended for	$\uparrow \uparrow$	100 %
the topical treatment of rosacea.		

Ivermectin is a semi-synthetic derivative of avermectin and has been used as a preventative or therapeutic medication in tropical medicine since 1987, for millions of people with parasitic diseases such as onchocercosis (river blindness) or Loa Loa filariasis (African eye worm). In 1994 (at that time off-label) it was also identified as an effective and safe therapeutic for severe forms of scabies (scabies crustosa) which is predominantly seen in immunocompromised patients [42]. Oral use in severe human scabies and for combating scabies outbreaks was approved in Germany in 2015 (see AWMF guideline scabies 013-052).

The efficacy of ivermectin in rosacea is probably due to two different elements. On the one hand, the macrolide structure of the ivermectin molecule indicates an anti-inflammatory effect (anti-inflammatory effects are also known from other macrolides such as erythromycin, tacrolimus, and pimecrolimus), on the other hand ivermectin displays strong neurotoxic effects limited exclusively to non-vertebrates, so these parasites are eliminated within a short time. In rosacea, saprophytic hair follicle mites from the *demodex* species are the target for antiparasitic treatment. It has been shown that demodex mites play an important role in the pathogenesis of rosacea [43–45]. Reducing the number of mites can achieve significant improvement of the skin in rosacea patients. Permethrin (see below) for the treatment of rosacea presumably works in the same manner.

In Germany, 1% ivermectin cream was approved for treating papulopustular rosacea in adult patients in 2015. In the two parallel, randomized, double-blind, placebo-controlled pivotal trials [46], ivermectin was significantly superior to the control group treated with only the cream base in a total of 1,371 participants. The effect on inflammatory papulopustular eruptions appeared after only two weeks of treatment and showed superiority versus treatment with the cream base after twelve weeks (decrease of inflammatory eruptions compared with base value by 76 % respectively 75 %, with 50 % in the control group, p < 0.001 in both parallel studies).

As opposed to creams with metronidazole or azelaic acid, ivermectin cream is only used once a day and shows especially good results in severely inflammatory rosacea with papules and pustules.

Schaller et al. (2020) have successfully used ivermectin 1 % cream combined with low-dose doxycycline (40 mg/day) for severe rosacea [47].

#### Other topical preparations (off-label for rosacea)

#### Minocycline

Minocycline is a semi-synthetic tetracycline antibiotic. After successful systemic and topical use in acne vulgaris, it was also studied for rosacea with papules and pustules. Minocycline displays bacteriostatic and anti-inflammatory effects as well as inhibitory effects on vasodilation and granuloma formation. It is also considered a potent neutralizer of free oxygen radicals [48].

In May 2020, a foam with 1.5 % minocycline was approved in the USA for treating rosacea with papules and pustules. At this point in time, direct comparative studies against azelaic acid, metronidazole, or ivermectin in treating rosacea are not yet available [48].

#### Permethrin

Considering the role of demodex mites in the etiopathology of rosacea, clinical studies have investigated permethrin, an antiparasitic from the pyrethrin group, which is used as a topical treatment for scabies mites and lice [49–51]. In a twelve-week, double-blind split face study, 20 patients with papulopustular rosacea were treated with 5 % permethrin cream versus the cream base [51]. A significant reduction of demodex mites and rosacea symptoms was observed.

#### Clindamycin

Topical use of clindamycin (1 % cream) in papulopustular rosacea did reduce the number of papules, pustules, and nodules [52], but as with the other systemically used antibiotics erythromycin and tetracycline, topical use should if possible be avoided to prevent sensitization and development of resistance. In a placebo-controlled, randomized multicenter phase II study, 639 rosacea patients were treated with clindamycin cream at concentrations of 0.3 % or 1 %. An anti-inflammatory effect could not be confirmed with treatment either once a day or twice a day [53].

#### Topical retinoids: Adapalene and retinaldehyde

Topical retinoids have been studied in papulopustular rosacea based on their anti-inflammatory and keratolytic effects.

As compared with 0.75 % metronidazole gel, adapalene 0.1 % gel showed a more pronounced effect on inflammatory lesions but was inferior in reducing erythema [54]. Adapalene may potentially have a much delayed effect compared with metronidazole [55].

Therapeutic studies with topical retinaldehyde (0.05 % cream) in 23 women over a period of six months however showed a beneficial effect on the vascular component of rosacea: Improvement of erythema was reported in about 75 % of patients after five months of treatment (p < 0.05) [56].

#### Calcineurin inhibitors

The anti-inflammatory effects of the calcineurin inhibitors tacrolimus and pimecrolimus are the rationale for using these compounds in rosacea patients. They are used specifically for steroid-induced rosacea, partly to avoid a strong inflammatory rebound after discontinuation of glucocorticosteroids. Tacrolimus is used as 0.03 % cream or 0.1 % ointment [57–59], pimecrolimus as a 1 % cream [60–64]. The less fatty cream appears to be better tolerated on the face,

compared with the ointment base. Some dermatologists therefore prescribe tacrolimus in a modified base for use on the face. In an open clinical comparison, pimecrolimus 1 % cream showed comparable effects to 1 % metronidazole cream [63] and was well tolerated.

Apart from a handful of studies on rosacea treatment with tacrolimus, there have also been reports on the induction of rosacea-like dermatitis [65] and also granulomatous rosacea [66] by tacrolimus.

In an open study, pimecrolimus was used successfully in mild to moderate rosacea, reducing the score of papulopustular eruptions as well as erythema [64], but the compound can also induce rosacea-like dermatitis [67].

Due to the immunosuppressive effect of tacrolimus, periocular herpes simplex infection has been reported in a small number of cases – particularly after treatment of atopic dermatitis on the face.

In summary, the current database does not appear sufficient to either recommend or reject the use of calcineurin inhibitors for rosacea.

#### Benzoyl peroxide

In rosacea patients with more robust skin, benzoyl peroxide may result in an improved clinical appearance. However, in patients with sensitive skin the opposite effect was reported [59]. Combinations of benzoyl peroxide with clindamycin or erythromycin have also been studied for treatment of rosacea [68]. Leyden reported on a randomized, vehicle-controlled, double-blind multicenter study with encapsulated benzoyl peroxide at concentrations of 1 % or 5 % in 92 patients with mostly moderate papulopustular rosacea. Once-daily use of either concentration over a period of twelve weeks resulted in a significant decrease of papules and pustules, and in the case of the 5 % gel also in a reduction of the rosacea score to "healed or nearly healed" [69].

#### **Topical maintenance treatment**

Since rosacea is a chronic-inflammatory facial dermatosis, it shows a tendency to relapse after treatment has been discontinued. Skin improvements achieved through intensive systemic or combined systemic/topical treatment can be maintained for longer periods of time by topical maintenance treatment. Metronidazole has proven to be effective for successful maintenance treatment [70]. Long-term treatment studies with brimonidine 0.33 % gel and ivermectin 1 % cream have been conducted at standard doses over periods of 6–12 months each.

### Systemic treatment

Recommendation	Strength	Consent
Systemic treatment is recommen-	$\uparrow \uparrow$	100 %
ded for treatment-refractory and		
severe forms of papulopustular		
rosacea.		

Systemic treatments should be used in particular for severe forms or milder but treatment-refractory forms of rosacea. The most frequently used drugs, at this point in time, are tetracyclines, specifically doxycycline and minocycline. The only approved preparation for the treatment of rosacea is 40 mg doxycycline at an anti-inflammatory dosage and with modified drug release.

#### Tetracyclines

Recommendation	Strength	Consent
Low-dose doxycycline is recom-	$\uparrow \uparrow$	100 %
mended as the systemic treatment		
of choice.		

#### First generation

Tetracyclines have been used in the treatment of rosacea for decades. Twice-daily intake of 250 mg over a period of four weeks resulted in a significant improvement of skin appearance in 78 % of patients with papulopustular rosacea. Stable disease was achieved by daily intake or intake every other day of 250 mg tetracycline (sensu stricto). However, recurrence rates after discontinuation are high [71]. Antibiotic treatment is very effective against the inflammatory component of rosacea (papules and pustules), but the effect on erythema and teleangiectasia is poor. Tetracycline can be used at doses of 250-1000 mg per day [72]. According to current understanding, the efficacy of tetracyclines is due to non-antibiotic mechanisms of action. The molecular mechanism of action displayed by doxycycline may be based on inhibiting the proteolytic activation of peptidases related to kallikrein, which play an important role in the development or rosacea, as well as inhibiting activation of cathelicidine. This may mediate the anti-inflammatory effect of doxycycline [73] (see section: Pathogenesis).

#### Second Generation

The second generation of tetracyclines (minocycline, doxycycline) shows similar efficacy against inflammatory lesions in rosacea. As compared with first-generation tetracycline, these drugs offer the benefits of better bioavailability and longer half-life. These tetracyclines can also be taken with food, thus reducing gastrointestinal side effects [74]. In the treatment of rosacea, doxycycline and minocycline are used (off label) at higher dosages of 100–200 mg per day [72].

#### Low-dose doxycycline treatment

The only approved medication for systemic treatment of papulopustular rosacea is currently 40 mg doxycycline with modified drug release. The 40 mg preparation is based on a galenic formulation combined from 30 mg with immediate release and 10 mg with retarded release. The solitary potency and the special galenic formulation result in different bioavailability and thus therapeutically significant differences. When used as intended, this drug does not have an antimicrobial effect [75]. Due to its clinically relevant sub-antimicrobial dosage, this treatment option is also called "anti-inflammatory doxycycline therapy" [76]. 40 mg doxycycline with modified drug release is the preferred treatment option based on the results of clinical trials and the approval in this indication.

This is also important for patients who reported side effects (candida infection, gastrointestinal side effects, sensitivity to light, hyperpigmentation) with earlier antibiotic treatments. According to a Cochrane review, there is high evidence in favor of the efficacy and safety of doxycycline in both low doses (40 mg per day) and conventional doses (100 mg per day) [77].

Two pilot studies with doxycycline at anti-inflammatory doses also found very high efficacy in ocular rosacea [78, 79].

Van der Linden et al. showed that minocycline 100 mg/ day was non-inferior to sub-antimicrobial doxycycline 40 mg/day for the treatment of mild to severe papulopustular rosacea [80]. However, 100 mg minocycline is still not really suitable for treating rosacea due to possible hyperpigmentation of the skin and teeth, and some very rare but very severe potential side effects such as drug-induced lupus erythematosus or hypersensitivity syndrome [81]. The benefit-risk balance of doxycycline is thus much more favorable than that of minocycline. Minocycline should thus no longer be considered a first-line treatment for inflammatory dermatoses [82].

#### Macrolides

As an alternative, especially in cases of tetracycline intolerance, treatment refractory rosacea, or contraindications such as pregnancy, macrolides like erythromycin, clarithromycin, and azithromycin may be used.

Oral application of 250–1000 mg erythromycin per day is considered an effective treatment for papulopustular rosacea but is rarely recommended due to the frequent occurrence of gastrointestinal side effects [72]. Erythromycin should thus be used only for patients who have contraindications against tetracyclines [55]. Azithromycin and clarithromycin are chemically more stable than the "older" erythromycin and are usually better tolerated.

250 mg clarithromycin twice a day for four weeks followed by 250 mg once a day for another four weeks effectively reduced both erythema and papules and worked faster than doxycycline [83].

Azithromycin has an affinity to inflamed tissue and has fewer side effects than other macrolide antibiotics. It reduces neutrophil migration, inhibits neutrophil and eosinophil activation, and suppresses both the release or reactive oxygen species and the formation of pro-inflammatory cytokines, and thus has an overall anti-inflammatory effect.

After twelve weeks of azithromycin treatment at decreasing doses, skin appearance was improved by 75 % and inflammatory lesions reduced by 89 % as compared to baseline [84].

In another study with patients who had papulopustular and ocular rosacea, a significant improvement of the ocular symptoms was achieved after only four weeks of treatment with azithromycin (500 mg three times a week) [84].

Due to a low quality of the studies, however, the Cochrane review categorizes the evidence level as "very low" [77], so the efficacy of azithromycin must be confirmed by future high-quality studies.

#### Metronidazole

Metronidazole 200 mg twice a day combined with 1 % hydrocortisone cream over a period of six weeks improved the severity level of rosacea in 10 out of 14 patients [85]. During metronidazole treatment, a disulfiram-like effect may cause alcohol-induced headaches. Thus alcohol should be avoided [86].

#### **Other antibiotics**

Studies have also shown efficacy for co-trimoxazole, clindamycine, chloramphenicol, and ampicillin. Experience however is limited and thus use of these compounds should be restricted [86, 87].

Small Intestinal Bacterial Overgrowth (SIBO) is significantly more common in rosacea patients than in control persons (46–51 % versus 5–23 %). Based on this association, there have been several reports on successful rosacea treatment with rifaximine [88].

#### Isotretinoin

Recommendation	Strength	Consent
Low-dose isotretinoin (0.1–0.3 mg/	$\uparrow$	100 %
kg body weight [BW] is suggested		
as a systemic treatment for rosacea		
(off label).		

Isotretinoin, a retinoic acid isomer, has been successfully used to improve rosacea in several studies [89-92]. As compared with antibiotics, however, the onset of effect may be delayed. Use of isotretinoin results in a substantial reduction of papules, pustules, and erythema [93]. Reduction of erythema may however be masked by isotretinoin-induced dermatitis and xerosis. According to laser Doppler examinations, skin blood flow in the facial skin is reduced. Even reduction of rhinophyma has been achieved [94]. As opposed to the standard dosage of 0.5-1.0 mg/kg BW per day, low-dose treatment with 10 to 20 mg daily can be just as successful and has a markedly reduced side effect profile. Isotretinoin has long been acknowledged as an effective drug for the systemic treatment of severe rosacea, but due to the lack of evidence-based clinical studies remains off label in this indication. In a large and methodically valid dose-finding and efficacy study [18] on the treatment of phenotype II and III rosacea with isotretinoin, this retinoid proved an excellent option for the systemic treatment of severe and moderate forms of rosacea. An isotretinoin dose of 0.3 mg/ kg BW/day was shown to be effective with significant superiority over placebo and non-inferiority compared with doxycycline. Other studies confirmed a high efficacy of isotretinoin at low doses of 10-20 mg per day in the treatment of papulopustular rosacea, but also in cases of extrafacial location [95] and in patients whose rosacea had not responded to antibiotic treatment [96]. Due to the large database, evidence quality is considered high [77]. Based on our own observations, low-dose isotretinoin treatment with 10 mg per day is not contraindicated in ocular rosacea but leads to improvement of ocular symptoms in most patients. Isotretinoin is currently not approved for rosacea treatment, and simultaneous treatment with tetracyclines is strictly contraindicated. Due to the embryotoxic effect of isotretinoin, reliable contraception is mandatory when treating women of reproductive age.

#### Glucocorticoids

Glucocorticoids are not indicated for rosacea and may even worsen this disease. Exacerbation has been observed after discontinuing corticosteroids (steroid rosacea) [97]. The only exception is short-term use in rosacea fulminans.

#### **Beta blockers**

Recommendation	Strength	Consent
Carvedilol may be considered for	О	100 %
systemic treatment of persistent		
erythema and flushing in rosacea		
(off label).		

Beta blockers such as propranolol (a non-selective  $\beta$  receptor blocker) or carvedilol (a non-selective  $\beta$  receptor blocker with  $\alpha_1$ -antagonistic activity) are usually indicated for arterial hypertension, coronary heart disease, angina pectoris, and tachycardia.

In rosacea, beta blockers mainly reduce erythema respectively flushing. This effect is based on a number of factors. Blocking  $\beta$ -adrenergic receptors in the smooth muscles of cutaneous blood vessels leads to vasoconstriction. Anxiety and tachycardia, which can exacerbate flush symptoms, are mitigated as well. Carvedilol has additional antioxidative and anti-inflammatory properties.

There are several indications that systemic beta blocker treatment is effective for rosacea. Hsu and Lee treated eleven normotensive patients who had rosacea erythemato-teleangiectatica with carvedilol in slowly increased doses up to a maximum of 31.25 mg per day. Within three weeks, all patients showed a significant improvement of their symptoms [98]. Another case series with five patients confirmed these results [99].

In a retrospective analysis of nine patients with idiopathic or rosacea-associated flushing who were treated with propranolol (initially 10 mg 3 times a day, then slowly increased to 20–40 mg 2–3 times a day), complaints improved. However, several patients reported side effects such as vertigo, fatigue, and bradycardia [100]. At this point in time, the sparse database does not support a recommendation for the use of beta-blockers.

### Combined treatment

The relevant section can be found in the AWMF long version of this guideline.

### Alternative treatment options

The relevant section can be found in the AWMF long version of this guideline.

### Physical therapies

The specific recommendations can be found in the relevant section of the AWMF long version of the guideline "laser therapy of the skin".

## Ocular rosacea - clinical presentation

#### Epidemiological data

Ocular rosacea may occur either simultaneously with cutaneous disease (about 20-50 %), or as an isolated finding (up to 90 % in ophthalmological examinations). The relevant aspects of underlying multifactorial pathophysiology are analogous to cutaneous rosacea [101]. Data on incidence show a large variation between dermatological and ophthalmological studies and range from 6–72 % [102, 103]. Eye involvement can significantly impair quality of life [104].

#### **Clinical presentation and symptoms**

Ocular symptoms of rosacea are usually bilateral and frequently independent of the clinical severity of cutaneous symptoms [105, 106]. Several studies, however, have reported a significant association between the ophthalmological findings and the severity of teleangiectasia [107, 108]. The incidence of recurrent chalazion is increased [105]. Clinical changes are dominated by Meibomian gland dysfunction (MGD) with various degrees of inflammation on the surface of the eye. Slit-lamp examination of the eyelid margins shows teleangiectasia, enlarged Meibomian glands, excessive seborrheic secretion, and "collarettes". Meibomographies have verified a significantly reduced density of Meibomian glands [108, 109]. MGD results in alteration of the lipid composition of the tear film, with increased evaporation of tear fluid, reduced tear break-up time, and evaporative, dry eyes [102, 103, 105, 110]. If the tear film is significantly altered, chronic conjunctivitis frequently results, and in some individual cases fibrosing will lead to a pemphigoid-like appearance. Episcleritis and anterior uveitis are other rare occurrences [4]. Now and then, eyelid or periorbital edema may occur and give rise to a suspicion of Morbihan disease [111].

#### **Symptoms**

Recommendation	Strength	Consent
Ocular rosacea is a clinical diagnosis.	Statement	100 %
Clinical indications of ocular rosa- cea include posterior blepharitis, Meibomian gland dysfunction, and secondary inflammatory ch-	Statement	100 %
ange(s) of the ocular surface.		

The symptoms of ocular rosacea result from the MGD and the ensuing "evaporative dry eye". Complaints frequently start early in the day and thus may offer an indication regarding the differential diagnosis of hypovolemic dry eye. In the latter case, symptoms frequently increase during the later part of the day. The complaints are non-specific and present as foreign body sensation, dry, burning, or tearing eyes, and erythema of the eyelid margins. In cases of severely compromised tear film, this may lead to varying visual impairment with blurred vision and increased sensitivity to light.

#### Diagnostics

Ocular rosacea is a clinical diagnosis based on one or more findings and symptoms. There is no specific test to confirm the suspected diagnosis. Clinical signs include posterior blepharitis, MGD, and secondary inflammatory change(s) of the ocular surface. Objective methods for assessing the severity of MGD and the extent of gland decline are available [108] (Meibography). Meibometry can measure the amount of oil in the eyelid margin reservoir [112]; however both methods offer only limited specific indications [113, 114].

### Ocular rosacea – treatment

Recommendation	Strength	Consent
The indication for treating ocular rosacea depends on the severi- ty of ocular involvement and is frequently independent of skin symptoms.	Statement	100 %
Recommendation	Strength	Consent
Eyelid margin hygiene <b>is recom</b> - <b>mended</b> as a general practice.	$\uparrow \uparrow$	100 %
Recommendation	Strength	Consent
Ciclosporin eye drops as well as azithromycin <b>are suggested</b> for the topical treatment of inflammation on the ocular surface (off label). Ivermectin or metronidazole (skin cream) <b>is suggested</b> for topical application on the eyelids (off label).	Ţ	100 %
Recommendation	Strength	Consent
Doxycycline or azithromycin as well as other macrolide anti- biotics <b>is suggested</b> for systemic treatment (off label).	Ŷ	100 %
Recommendation	Strength	Consent
Systemic treatment with ivermec- tin, with or without metronidazo- le and omega-3 fatty acids, <b>may</b> <b>be considered</b> for ocular rosacea (off label).	0	100 %
Recommendation	Strength	Consent

Recommendation	strength	Consent
Intense Pulsed Light treatment may	0	100 %
be considered for ocular rosacea.		

There are no randomized controlled trials (RCT) on the best compounds or the optimal duration of treatment for ocular rosacea. The indication depends on the severity of ocular involvement. In mild forms of ocular rosacea, topical ophthalmological treatment should suffice. Eyelid margin hygiene is recommended (Guideline No. 11, Dry Eye, BVA and DOG, 2019) [115, 116]. This can be supported by warming of the eyelid margins to liquefy the secretions in the Meibomian glands. Use of lipid-containing artificial tears is recommended as a supporting practice. Various topical medications have been used to treat inflammation in ocular rosacea.

One study in 37 patients showed that ciclosporin eye drops 0.05 %, used twice a day over a period of three months, improved the objective ocular parameters measured by Schirmer's test (p = 0.001) and a prolonged tear break-up time (TBUT) (p = 0.001). Patients' quality of life improved significantly (p = 0.01) [117].

Via its influence of metalloproteinases, the antibiotic azithromycin 1.5 % (Azyter<sup>®</sup>), (twice a day on the first two days, once a day thereafter over a period of four weeks) also showed improvement of blepharitis in non-controlled studies [118].

Other non-controlled studies with the calcineurin inhibitor pimecrolimus (skin cream, Elidel<sup>®</sup>) and with metronidazole also showed positive results in reducing inflammation. The preparations are applied to the eyelid margins.

If complaints persist, or if skin involvement justifies this form of treatment, doxycycline (50–100 mg twice a day) has proven effective. In a pilot study, doxycycline at anti-inflammatory doses (2x 40 mg per day in week one, and 40 mg once a day thereafter) proved very effective in treating ocular rosacea [78]. Erythromycin appears to offer good results in young patients and in those with doxycycline/tetracycline intolerance [119]. Non-controlled studies have also shown efficacy of systemic clarithromycin and metronidazole.

Under the premise that *demodex folliculorum* is a crucial factor in the development of blepharitis, oral ivermectin (200  $\mu$ g/kg), occasionally also in combination with oral metronidazole (250 mg three times a day for two weeks) has also been used successfully [120]. Topical ivermectin has also shown very good results in a non-controlled study [121]. However, no RCTs for either form of application are currently available.

To be effective in ocular involvement, any systemic treatment must be used for a long period of time. The first visible effect can be expected after a minimum of 6–8 weeks, and treatment durations of about 3–6 months are often required.

Different effects for systemic supplementation of omega-3 fatty acids in ocular rosacea have been observed. In a randomized controlled trial (n = 130), systemic treatment with omega-3 fatty acids (180 mg eicosapentaenic acid and 120 mg docosapentaenic acid), one capsule twice a day was compared with placebo. The ophthalmologic parameters showed a beneficial effect of the omega-3 fatty acids. Evaluation of a questionnaire

on the subjective assessment of "dry eyes" showed that patients preferred the omega-3 fatty acids over placebo (p < 0.001). A previous meta-analysis [122] however had not found any effect in six out of seven studies. Another randomized, controlled, double-blind study in a total of 449 patients with keratoconjunctivitis sicca, omega-3 fatty acids did not show any statistically significant benefit compared with placebo [123].

In recent years, there have been several publications on studies treating MGD diseases including ocular rosacea with intense pulsed light (IPL) [124].These have not at this point in time led to recommendations; further studies are required.

## Treatment of special forms

The relevant section can be found in the AWMF long version of this guideline.

## Psychosocial aspects

The relevant section can be found in the AWMF long version of this guideline.

## Differential diagnoses

Table 4 offers an overview of differential diagnoses.

## Dermocosmetics

Cosmetics are defined as substances or mixtures that are intended for external use on the human body to cleanse or protect the skin, keep it in good condition, or change its appearance [125]. In the context of this guideline, this chapter covers cosmetics which offer a meaningful non-medical contribution to the successful management of rosacea. Use of appropriate dermocosmetics is crucial [126–132]. Ideally, all cosmetics (cleansers, skin care, sunscreens, and others) should be tailored to the skin's needs both during active relapses and during remission intervals.

Patients should be advised to prefer products for sensitive skin, or even products recommended especially for rosacea (medical cosmetics).

Dermocosmetic routines should be followed in the morning and at night, always in the order cleansing – skin care – sunscreen.

#### Cleansing

Recommendation	Strength	Consent
Gentle cleansing is recommended	$\uparrow \uparrow$	100 %
(tepid water, synthetic detergents		
adapted to the pH of healthy skin,		
patting the skin dry).		

#### Table 4Differential diagnoses.

Rosacea erythemato- teleangiectatica	<ul> <li>Polycythemia vera (increased blood values: hemoglobin, hematocrite, erythrocytes)</li> <li>Lupus erythematosus (direct immunofluorescence, ANA, hemogram)</li> <li>Dermatomyositis (LDH, creatine kinase, ANA, anti-Jo1)</li> <li>Mixed connective tissue disease (ANA, rheumatoid factor, U1-RNP antibodies)</li> <li>Carcinoid syndrome, for example from neuroendocrine tumors (5-hydroxyindole acetic acid excretion in 24-hour urine, serotonin in serum, imaging)</li> <li>Mastocytosis (histology: mast cell infiltration in the corium, serum tryptase, N-methylhistamine, respectively 1,4-methylimidazole acetic acid in 24-hour urine)</li> <li>Allergic contact eczema (medical history, patch testing)</li> <li>Arterial hypertension (measuring blood pressure)</li> <li>UV-induced damage of cutaneous vessels (medical history)</li> </ul>
Papulopustular rosacea	<ul> <li>Papulopustular acne (comedones present, age)</li> <li>Perioral dermatitis (eyes/mouth are spared, usually excessive skin care</li> <li>Allergic or toxic contact eczema (medical history, patch test)</li> <li>Gram-negative folliculitis (detection of gram-negative bacteria from pustules)</li> <li>Eosinophilic folliculitis (histology: eosinophilic infiltration, eosinophils detected in the blood count, lgE)</li> <li>Folliculitis et perifolliculitis capitis suffodiens et abscedens (distribution, hair loss, abscesses)</li> <li>Demodicosis (mostly unilateral/asymmetric, detection of demodex mites, more acute dynamics)</li> </ul>
Rosacea phymatosa	<ul> <li>Lupus pernio/sarcoidosis (serum ACE concentration, soluble interleukin-2 receptor in serum, histology: epitheloid cell granuloma)</li> <li>Eosinophilic granuloma (computed tomography, immunohistochemistry)</li> </ul>

Recommendation	Strength	Consent
It is recommended to avoid ir-	$\uparrow \uparrow$	100 %
ritation when cleansing, such as		
scrubbing, peelings, substances		
that promote blood circulation, or		
adstringents.		

Skin cleansing in the morning and at night should be as gentle as possible. Because of possible vascular hyperreactivity and irritability of the skin, water should always be tepid and the skin should be dried by gentle patting [129].

Only "syndets" (synthetic detergents) with a slightly acidic pH similar to that of healthy skin should be used. Common cosmetic detergents with irritative potential, for example sodium lauryl sulfate, should be avoided [126, 129, 131–136]. Even plain water may remove a significant amount of natural moisturizing factors (NMF) from the skin when "rinse-off" cleansing products are used, so patients describe an uncomfortable feeling of tension. These NMF, such as amino acids, salts, glycerin, or urea, naturally occur in the skin and can be preserved by using cleansing fluids or micellar waters that are used without additional water (leave-on products).

Any irritation, such as scrubbing the skin, coarse washcloths or towels, mechanical or chemical peelings, as well as substances promoting blood circulation or irritating substances (such as alcohol, essential oils, menthol, camphor, certain fragrances and preservatives) should of course be avoided [126, 131, 133].

#### Skin care

Recommendation	Strength	Consent
Light/hydrophilic skin care pre- parations <b>are recommended</b> for patients with rosacea.	$\uparrow \uparrow$	100 %
Recommendation	Strength	Consent
Cosmetics with active ingredients to improve complaints in rosacea <b>are suggested</b> .	¢	100 %
Recommendation	Strength	Consent
It <b>is recommended</b> to avoid irrita- ting cosmetics and those promo- ting blood circulation.	↑↑	100 %

Rosacea patients should prefer hydrophilic skin care products; emulsions should be O/W (oil in water), with a low oil content [126, 133, 137].

Excessive oil content is occlusive and may thus aggravate complaints in rosacea [131], but appropriate skin care can

provide a fundamental contribution in alleviating symptoms such as tension, burning, or discomfort [129, 131, 132, 138].

"Medical cosmetics" sold in pharmacies also contain so-called active cosmetic ingredients (cosmeceuticals) that claim medical efficacy yet can only be marketed as cosmetics. Manufacturers offer products with anti-inflammatory, skin-calming, or vessel-stabilizing properties such as retinaldehyde, licocalchone A, or kinetin [56, 139, 140]. UV filters, usually with SPF 20 to 30, can be found in skin care products but can of course also be added after application of skin care products (see section below).

Just as in cleansing, irritating formulas should be avoided. These include products promoting blood circulation, "anti-ageing" products, but also creams for dry and atopic skin (with a high lipid content) and products for blemished skin (with keratolytics like glycolic acid or salicylic acid).

#### Sunscreen

Recommendation	Strength	Consent
Daily use of a broad-spectrum sun-	$\uparrow \uparrow$	100 %
screen with both UV-A and UV-B		
protection is recommended.		

Since UV radiation is a common trigger factor for rosacea, use of appropriate sunscreens is generally recommended. This not only applies to sunny summer days but also cloudy days and the winter months. Since hats are the only clothing article that can protect the face, and sunlight cannot always be avoided, the face should be protected with cosmetic sunscreens at all times. These are sometimes contained in skin care products, but in most cases only with a moderate sun protection factor (SPF 20–30). For longer times spent outdoors, use of higher sun protection factors is recommended.

Apart from using appropriately high sun protection factors with moderate (SPF 20–30) to high (SPF 50–50+) protection, it is important to use these products correctly and consider the chemical properties of the UV filters as well as the cosmetic base.

#### Additional dermocosmetic practices

Recommendation	Strength	Consent
It is recommended to use decora-	$\uparrow \uparrow$	100 %
tive cosmetics if this contributes to		
improved quality of life.		

In general, any further cosmetic procedures should be as gentle as possible so as not to cause irritation.

If feasible, decorative cosmetics should be kept to a minimum so any unnecessary irritation can be avoided. Skin care products for rosacea frequently already have a greenish tinge to counteract the redness of erythema after application. Since outward appearance contributes considerably to a decreased quality of life in rosacea patients, such products can improve quality of life significantly [141, 142]. Note that the formulation of decorative cosmetics need to be considered as well – light powders or creams are preferable to heavy, lipid-rich products (such as "camouflage" creams) even though the latter offer more coverage for erythema.

Thermal water sprays are another cosmetic product suitable for acute use. Rosacea patients with irritated skin and a sensation of heat can spray these products on the skin as required, several times a day. Rapid evaporation conveys a feeling of refreshment and cooling. In addition, *in vitro* and *in vivo* studies have shown anti-inflammatory, anti-angiogenetic, and calming effects with improved quality of life [143– 147]. These are probably based on the special mineral and microbial composition of the natural healing waters.

Shaving the face is a topic which must be discussed with male rosacea patients. Dry shaving is preferable to wet shaving since the latter causes micro-trauma of the skin surface and thus impairs the skin barrier. Alcoholic after-shaves should be avoided because of their irritating properties.

## Acknowledgement

Open access funding enabled and organized by Projekt DEAL.

#### Conflict of interest

Conflicts of interest are listed in the AWMF long version.

Correspondence to

Privatdozent Dr. med. Markus Reinholz, Ph.D., FEBDV Department and Clinic for Dermatology and Allergology University Hospital Munich, LMU Munich Frauenlobstraße 9–11

80337 München Germany

E-mail: markus.reinholz@med.lmu.de

#### References

- Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G et al. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. Z Evid Fortbild Qual Gesundhwes 2014; 108: 413–20.
- Reinholz M, Tietze JK, Kilian K et al. Rosazea-S1-Leitlinie. J
   Dtsch Dermatol Ges 2013; 11: 768–79.
- 3 Schaller M, Schofer H, Homey B et al. Rosacea Management: Update on general measures and topical treatment options. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 17–27.
- 4 Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012; 167: 598–605.

- 5 Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018; 179: 282–9.
- Augustin M, Herberger K, Hintzen S et al. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers.
   Br J Dermatol 2011; 165: 865–73.
- 7 Alexis AF, Callender VD, Baldwin HE et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol 2019; 80: 1722–29 e7.
- 8 Elewski BE, Draelos Z, Dreno B et al. Rosacea global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188–200.
- 9 Van Steensel MAM, Badeloe S, Winnepenninckx V et al. Granulomatous rosacea and Crohn's disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W. Exp Dermatol 2008; 17: 1057–8.
- 10 Yamasaki K, Di Nardo A, Bardan A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13: 975–80.
- 11 Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011; 15: 12–5.
- Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol 2017; 26: 659–67.
- 13 Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: S15–26.
- 14 Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584–7.
- 15 Zierl S, Guertler A, Hildebrand JA et al. A comprehensive epidemiological study of rosacea in Germany. Eur J Dermatol 2021; 31(6): 744–51.
- 16 Reinholz M, Ruzicka T, Steinhoff M et al. Pathogenese und Klinik der Rosazea als Schlüssel fur eine symptomorientierte Therapie. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 4–16.
- Schaller M, Almeida LMC, Bewley A et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol 2020; 182: 1269–76.
- 18 Gollnick H, Blume-Peytavi U, Szabó EL et al. Systemic isotretinoin in the treatment of rosacea – doxycycline- and placebocontrolled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8: 505–15.
- 19 Tan J, Almeida LM, Bewley A et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176: 431–8.
- 20 van Zuuren EJ, Fedorowicz Z, Tan J et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 2019; 181: 65–79.
- 21 Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents

for rosacea: a survey-based study. Am Health Drug Benefits 2018; 11: 97–106.

- 22 Gallo RL, Granstein RD, Kang S et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2018; 78: 148–55.
- 23 Fowler J, Jarratt M, Moore A et al. Once-daily topical brimonidine tartrate gel 0.5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166: 633–41.
- 24 Fowler J, Jr., Jackson M, Moore A et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650–6.
- 25 Moore A, Kempers S, Murakawa G et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014; 13: 56–61.
- 26 Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea – aetiology, different pathophysiologies and treatment options. Acta Derm Venereol 2016; 96: 579–86.
- 27 Piwnica D, Rosignoli C, de Ménonville ST et al. Vasoconstriction and anti-inflammatory properties of the selective αadrenergic receptor agonist brimonidine. J Dermatol Sci 2014; 75: 49–54.
- 28 Gold LM, Draelos ZD. New and emerging treatments for rosacea. Am J Clin Dermatol 2015; 16: 457–61.
- 29 Patel NU, Shukla S, Zaki J, Feldman SR. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Rev Clin Pharmacol 2017; 10: 1049–54.
- 30 Draelos ZD, Gold MH, Weiss RA et al. Efficacy and safety of oxymetazoline cream 1.0 % for treatment of persistent facial erythema associated with rosacea: Findings from the 52week open label REVEAL trial. J Am Acad Dermatol 2018; 78: 1156-63.
- 31 Kircik LH, DuBois J, Draelos ZD et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0 % for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol 2018; 17: 97–105.
- Layton AM, Schaller M, Homey B et al. Brimonidine gel 0.33
   % rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 2015; 29: 2405–10.
- 33 Bjerke J, Nyfors A, Austad J et al. Metronidazole (Elyzol) 1-percent cream v. placebo cream in the treatment of rosacea. Clin Trials J 1989; 26: 187–94.
- 34 Breneman D, Stewart D, Hevia O et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998; 61: 44–7.
- 35 Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006; 5: 317–9.

- 36 Del Rosso JQ, Kircik LH. Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol 2014; 13: s101–7.
- 37 Del Rosso JQ. Azelaic acid topical formulations: differentiation of 15 % gel and 15 % foam. J Clin Aesthet Dermatol 2017; 10: 37–40.
- 38 Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis 2013; 92: 306–17.
- 39 Gupta AK, Gover MD. Azelaic acid (15 % gel) in the treatment of acne rosacea. Int J Dermatol 2007; 46: 533-8.
- 40 Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15 %) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836–45.
- 41 Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20 % cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol 1999; 79: 456–9.
- 42 Leyer A, Rieg G, Müller M et al. Ivermectin zur Behandlung der Skabies norwegica bei AIDS Patienten. Ein neues Therapiekonzept – dargestellt an 2 Fallbeispielen. AIDS-FORSC-HUNG (AIFO). 1994; 9: 608.
- 43 Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol 2010; 146: 896–902.
- 44 Steinhoff M, Buddenkotte J, Aubert J et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2–11.
- 45 Reinholz M, Ruzicka T, Steinhoff M et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Ges 2016; 14 (Suppl 6): 4–15.
- 46 Stein L, Kircik L, Fowler J et al. Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13: 316–23.
- Schaller M, Kemény L, Havlickova B et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol 2020; 82: 336–43.
- 48 van Zuuren EJ, Arents BWM, van der Linden MMD et al. Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 2021; 22: 457–65.
- 49 Signore RJ. A pilot study of 5 percent permethrin cream versus
   o.75 percent metronidazole gel in acne rosacea. Cutis. 1995;
   56: 177–9.
- 50 Koçak M, Yağli S, Vahapoğlu G, Ekşioğlu M. Permethrin 5 % cream versus metronidazole 0.75 % gel for the treatment of papulopustular rosacea. A randomized double-blind placebocontrolled study. Dermatology 2002; 205: 265–70.
- 51 Raoufinejad K, Mansouri P, Rajabi M et al. Efficacy and safety of permethrin 5 % topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2016; 30: 2105–17.
- 52 Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32: 65–7.

- 53 Martel P, Jarratt M, Weiss J, Carlavan I. Lack of significant antiinflammatory activity with clindamycin in the treatment of rosacea: results of 2 randomized, vehicle-controlled trials. Cutis 2017; 100: 53–8.
- 54 Altinyazar HC, Koca R, Tekin NS, Eştürk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005; 44: 252-5.
- 55 Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287–94.
- 56 Vienne MP, Ochando N, Borrel MT et al. Retinaldehyde alleviates rosacea. Dermatology 1999; 199 (Suppl 1): 53–6.
- 57 Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol 2009; 23: 239–40.
- 58 Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107–8.
- 59 Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499–512; quiz 13–4.
- 60 Lee DH, Li K, Suh DH. Pimecrolimus 1 % cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008; 158: 1069–76.
- 61 Chu CY. The use of 1 % pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396–9.
- 62 Cunha PR, Rossi AB. Pimecrolimus cream 1 % is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86: 71–2.
- 63 Koca R, Altinyazar HC, Ankarali H et al. A comparison of metronidazole 1 % cream and pimecrolimus 1 % cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2010; 35: 251–6.
- 64 Kim MB, Kim GW, Park HJ et al. Pimecrolimus 1 % cream for the treatment of rosacea. J Dermatol 2011; 38: 1135–9.
- 65 Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus-induced rosacealike dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology 2012; 224: 309–14.
- Hu L, Alexander C, Velez NF et al. Severe tacrolimus-induced granulomatous rosacea recalcitrant to oral tetracyclines. J Drugs Dermatol 2015; 14: 628–30.
- 67 El-Heis S, Buckley DA. Rosacea-like eruption due to topical pimecrolimus. Dermatol Online J 2015; 21.
- 68 Oztürkcan S, Ermertcan AT, Sahin MT, Aflar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol 2004; 31: 610–7.
- Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel.
   J Drugs Dermatol 2014; 13: 685–8.
- 70 Dahl MV, Katz HI, Krueger GG et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134: 679–83.
- 71 Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649–52.
- 72 Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007; 12: 1–5, 9.
- 73 Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol 2012; 132: 1435–42.

- Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 1991; 48: 411–7.
- Berman B, Perez OA, Zell D. Update on rosacea and antiinflammatory-dose doxycycline. Drugs Today (Barc) 2007; 43: 27-34.
- 76 McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010; 11: 217–22.
- 77 van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea. Cochrane Database Syst Rev 2015; 2015: Cd003262.
- 78 Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011; 9: 904–7.
- 79 Sobolewska B, Doycheva D, Deuter C et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea 2014; 33: 257–60.
- 80 van der Linden MMD, van Ratingen AR, vanRappard DC et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol 2017; 176: 1465–74.
- 81 Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329–42.
- 82 Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol 2012; 166: 1333–41.
- 83 Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36: 942–6.
- 84 Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 2009; 23: 544–9.
- 85 Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211–2.
- 86 Lehmann P. [Rosacea. Clinical features, pathogenesis and therapy]. Hautarzt 2005; 56: 871–85; quiz 86–7.
- 87 Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; 2: 1049–52.
- 88 Drago F, De Col E, Agnoletti AF et al. The role of small intestinal bacterial overgrowth in rosacea: A 3-year follow-up. J Am Acad Dermatol 2016; 75: e113–e15.
- 89 Nikolowski J, Plewig G. [Rosacea. Oral therapy with 13-cis retinoic acid]. Hautarzt 1980; 31: 660–1.
- 90 Schmidt JB, Raff M. [13-Cis-retinoic acid: a new form of treatment of rosacea (author's transl)]. Wien Klin Wochenschr 1982; 94: 115–8.
- 91 Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol 1984; 9: 484–8.
- 92 Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25: 660–3.
- 93 Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of lowdose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134: 884–5.
- 94 Jansen T, Regele D, Schirren CG et al. [Persistent erythema and edema of the face associated with rosacea and lymph vessel dysplasia]. Hautarzt 1998; 49: 932–5.

- 95 Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol 2010; 90: 409–10.
- 96 Sbidian E, Vicaut É, Chidiack H et al. A Randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol 2016; 136: 1124–9.
- 97 Melnik B, Jansen T. Akne und Rosazea. In: Plewig G, Landthaler M, Burgdorf: Braun-Falco's Dermatologie, Venerologie Und Allergologie. 6th Edition. Berlin and Heidelberg: Springer-Verlag, 2012.
- 98 Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker. J Am Acad Dermatol 2012; 67: 491–3.
- 99 Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat 2018; 29: 310–3.
- 100 Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53: 881–4.
- 101 Rodrigues-Braz D, Zhao M, Yesilirmak N et al. Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Mol Vis 2021; 27: 323-53.
- 102 Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003; 22: 230–3.
- 103 Vieira AC, Höfling-Lima AL, Mannis MJ. Ocular rosacea a review. Arq Bras Oftalmol 2012; 75: 363–9.
- 104 Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol 2014; 71: 973–80.
- 105 Oltz M, Check J. Rosacea and its ocular manifestations. Optometry 2011; 82: 92–103.
- 106 Lazaridou E, Fotiadou C, Ziakas NG et al. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatol Venereol 2011; 25: 1428–31.
- 107 Keshtcar-Jafari A, Akhyani M, Ehsani AH et al. Correlation of the severity of cutaneous rosacea with ocular rosacea. Indian J Dermatol Venereol Leprol 2009; 75: 405–6.
- 108 Palamar M, Degirmenci C, Ertam I, Yagci A. Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with rosacea. Cornea 2015; 34: 497–9.
- 109 Machalillska A, Zakrzewska A, Markowska A et al. Morphological and functional evaluation of meibomian gland dysfunction in rosacea patients. Curr Eye Res 2016; 41: 1029–34.
- 110 Knop E, Knop N, Brewitt H et al. [Meibomian glands: part III. Dysfunction – argument for a discrete disease entity and as an important cause of dry eye]. Ophthalmologe 2009; 106: 966–79.
- 111 Carruth BP, Meyer DR, Wladis EJ et al. Extreme eyelid lymphedema associated with rosacea (Morbihan disease): case series, literature review, and therapeutic considerations. Ophthalmic Plast Reconstr Surg 2017; 33: S34–8.
- 112 Geerling G, Baudouin C, Aragona P et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. Ocul Surf 2017; 15: 179–92.
- 113 Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea 2004; 23: 781–3.

- Mizoguchi S, Iwanishi H, Arita R et al. Ocular surface inflammation impairs structure and function of meibomian gland.
   Exp Eye Res 2017; 163: 78–84.
- 115 Geerling G, Tauber J, Baudouin C et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050–64.
- 116 Jones L, Downie LE, Korb D et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15: 575–628.
- 117 Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26: 651–9.
- 118 Haque RM, Torkildsen GL, Brubaker K et al. Multicenter openlabel study evaluating the efficacy of azithromycin ophthalmic solution 1 % on the signs and symptoms of subjects with blepharitis. Cornea 2010; 29: 871–7.
- 119 Gonser LI, Gonser CE, Deuter C et al. Systemic therapy of ocular and cutaneous rosacea in children. J Eur Acad Dermatol Venereol 2017; 31: 1732–8.
- 120 Salem DA, El-Shazly A, Nabih N et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis 2013; 17: e343-7.
- 121 Sobolewska B, Doycheva D, Deuter CM et al. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm 2021; 29: 1137–41.
- 122 Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit 2014; 20: 1583–9.
- 123 Asbell PA, Maguire MG, Pistilli M et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med 2018; 378: 1681–90.
- 124 Liu S, Tang S, Dong H, Huang X. Intense pulsed light for the treatment of Meibomian gland dysfunction: A systematic review and meta-analysis. Exp Ther Med 2020; 20: 1815–21.
- 125 Verordnung (EG) nr. 1223/2009 des europäischen Parlaments und des Rates vom 30. November 2009 über kosmetische Mittel. Amtsblatt der Europäischen Union, 2009.
- 126 Dermopharmazie GGf. Interdisziplinäres Management der Rosazea. 2014.
- 127 Schaller M, Belge, K. Rosazea Aktuelle Therapieoptionen im Blickpunkt. Hautnah Dermatologie 2013; 1: 27–33.
- 128 Kerscher M, Reuther T. Der Fluch der Kelten Kosmetische Aspekte bei der Rosazea. In: Schöfer H (Hrsg) Rosazea. Klinik und aktuelle Therapie. Stuttgart: Thieme Verlag, 2003: 67–72.
- 129 Borelli C, Korting HC. Nichtmedikamentöses Management der Rosazea. Hautarzt 2011; 62: 828–33.
- 130 Draelos ZD, Colón LE, Preston N et al. The appearance of facial foundation cosmetics applied after metronidazole gel 1 %. Cutis. 2011; 87: 251–9.

- 131 Levin J, Miller R. A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients. J Clin Aesthet Dermatol 2011; 4: 31–49.
- 132 Del Rosso JQ. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. Cutis 2005; 75: 17–21; discussion 33–6.
- 133 Raab W, Kindl U. Pflegekosmetik. Ein Leitfaden, 5. Aufl., Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2012.
- 134 Draelos ZD. The effect of Cetaphil Gentle Skin Cleanser on the skin barrier of patients with rosacea. Cutis 2006; 77: 27–33.
- 135 Draelos Z, Hornby S, Walters RM, Appa Y. Hydrophobically modified polymers can minimize skin irritation potential caused by surfactant-based cleansers. J Cosmet Dermatol 2013; 12: 314–21.
- 136 Schmid-Wendtner MH, Korting HC. pH and skin care, ABW Wissenschaftsverlag, Berlin, 2007.
- 137 Kresken J, Kindl U, Wigger-Alberti W et al. Dermocosmetics for use in rosacea: guideline of the society for dermopharmacy.Skin Pharmacol Physiol 2018; 31: 147–54.
- 138 Guertler A, Jontvedt NM, Clanner-Engelshofen BM et al. Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group. J Cosmet Dermatol 2020; 19: 2627–33.
- 139 Wu JJ, Weinstein GD, Kricorian GJ et al. Topical kinetin 0.1 % lotion for improving the signs and symptoms of rosacea. Clin Exp Dermatol 2007; 32: 693–5.
- 140 Weber TM, Ceilley RI, Buerger A et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 2006; 5: 227–32.
- 141 Seite S, Deshayes P, Dreno B et al. Interest of corrective makeup in the management of patients in dermatology. Clin Cosmet Investig Dermatol 2012; 5: 123–8.
- 142 Peuvrel L, Quereux G, Brocard A et al. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses. Dermatology 2012; 224: 374–80.
- 143 Karagulle MZ, Karagulle M, Kilic S et al. In vitro evaluation of natural thermal mineral waters in human keratinocyte cells: a preliminary study. Int J Biometeorol 2018; 62: 1657–61.
- 144 Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol 2013; 6: 23–8.
- 145 Eliasse Y, Redoules D, Espinosa E. Impact of Avene Thermal Spring Water on immune cells. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 21–26.
- 146 Mias C, Maret A, Gontier E et al. Protective properties of Avene Thermal Spring Water on biomechanical, ultrastructural and clinical parameters of human skin. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 15–20.
- 147 Nocera T, Jean-Decoster C, Georgescu V, Guerrero D. Benefits of Avene thermal hydrotherapy in chronic skin diseases and dermatological conditions: an overview. J Eur Acad Dermatol Venereol 2020; 34 (Suppl 5): 49–52.